There is a particular kind of achievement that belongs not just to those who accomplished it, but to the place that made it possible. The University of Queensland’s role in the development of the world’s first vaccine against human papillomavirus — the virus responsible for the overwhelming majority of cervical cancer cases — is one such achievement. It is not merely a feather in an institutional cap. It is a moral fact about what a public research university, embedded in a community and committed to the long work of science, can produce when circumstances, intellect, and institutional patience converge.

The story of the HPV vaccine is complex, disputed in parts, contested across jurisdictions, and shot through with tragedy. But at its core is a very Brisbane story: two researchers, working after hours in a laboratory at the University of Queensland’s Centre for Immunology and Cancer Research, chasing a biological problem that most of the scientific world had concluded was intractable. What they found, on a March evening in 1991, changed the trajectory of women’s health globally.

Understanding what that means — for Queensland, for Australia, and for the hundreds of millions of women now protected by vaccines flowing from that discovery — requires returning to the beginning, and to the particulars of a scientific problem that resisted conventional solution for decades.

THE PROBLEM THAT COULDN'T BE CULTURED.

Human papillomavirus had been identified as the causal agent of cervical cancer by German virologist Harald zur Hausen, whose work in isolating HPV strains from cervical tumours during the early 1980s would eventually earn him a Nobel Prize in Physiology or Medicine. The finding was significant, but it opened onto a practical problem that frustrated vaccine researchers: HPV is a virus that cannot be cultured in a standard laboratory setting without living tissue. The conventional vaccine-making toolkit — grow the virus, attenuate it, kill it, administer it — was simply unavailable. There was no obvious path from the knowledge that HPV caused cervical cancer to a means of preventing that infection.

Ian Frazer had arrived at the University of Queensland in 1985, taking up a Senior Lectureship with the opportunity to establish his own research laboratory. He had trained as a physician and clinical immunologist at the University of Edinburgh, immigrated to Australia in 1981 to research viral immunology at the Walter and Eliza Hall Institute in Melbourne, and come north to Brisbane with a growing interest in the specific question of why HPV infections in some patients persisted and progressed to cancer while in others they did not. By 1988, he had received his Doctor of Medicine and was running the Centre for Immunology and Cancer Research at UQ, conducting concurrent diagnostic work at the Princess Alexandra Hospital.

In 1989, on sabbatical in Cambridge, Frazer encountered Jian Zhou at the laboratory of Lionel Crawford. Zhou was a Chinese virologist and cancer researcher — meticulous, technically gifted in gene cloning and molecular expression, and working through related questions on papillomavirus biology. The two recognised in each other a shared preoccupation. Zhou was, in Frazer’s own later description, the person you went to in Crawford’s laboratory when a gene-cloning problem had resisted everyone else. He could do what others could not.

Frazer persuaded Zhou to join him in Brisbane, and in 1990 Zhou relocated to the University of Queensland, bringing with him a strain of HPV from the United Kingdom. Together, they turned to the core problem: since the virus could not be cultured, could molecular biology be used to synthesise something that looked like it — something that would prompt an immune response without containing the virus’s genetic material?

THE EUREKA THAT WASN'T ONE.

The virus-like particle — or VLP — is the conceptual heart of the HPV vaccine. The idea was not to use any part of the live virus, but to coax cells into producing the structural proteins of the viral outer coat, which would then self-assemble into particles that physically resembled the virus without carrying any of its DNA. A body presented with such a particle would mount an immune response. It would learn to recognise the virus. It would be, in effect, vaccinated — against a virus that no one had previously been able to include in a vaccine.

In March 1991, Xiao-Yi Sun — Zhou’s wife and a fellow researcher — assembled, following Zhou’s experimental design, two proteins (designated L1 and L2) into a virus-like particle resembling the outer shell of HPV. It was the first time this had been done. The result appeared under an electron microscope: something that looked exactly like the virus, without being the virus.

Years later, recalling that moment, Frazer described it with the particular understatement of a scientist who understood what he was looking at: the laboratory had produced an electron micrograph, and in it were the virus-like particles. Zhou said: “We’ve got the shell of the virus.” Frazer’s response was immediate — and so was his reasoning. “We knew that because we got something that looked like the virus,” he recalled, “there was a good chance that it could be a vaccine.”

The University of Queensland applied for a provisional patent in June 1991. In July of that year, Zhou and Frazer presented their findings at the International Conference on Human Papillomavirus in Seattle — and stunned their audience. The assembled scientists were, by contemporary accounts, both astounded and sceptical. But Harald zur Hausen himself was in the room, and he called it a breakthrough, a step toward a vaccine against cancer-causing HPV types. No less an authority had spoken. The patent was filed, the scientific record was publicly disclosed, and the field shifted.

The simplicity of the retrospective account, however, conceals the real texture of the achievement. Frazer would later reflect that what he and Zhou had understood — and what their Seattle presentation demonstrated — was that making a vaccine depended not on matching the protein sequence of the virus but on replicating its physical shape. As soon as they had something that looked like the virus, the vaccine pathway was open. By conventional means, this would have been impossible: without growing the virus, neither an attenuated nor a killed version could be made. The VLP approach circumvented the entire problem.

THE LONG ROAD FROM BENCH TO NEEDLE.

Scientific discovery and clinical deployment are separated by years, sometimes decades, of development, testing, regulatory navigation, and commercialisation. The HPV vaccine was no exception. Following the patent filing and public disclosure in 1991, years of further work at UQ were required before the technology was ready for clinical trials. The University’s commercial arm, UniQuest, licensed the intellectual property to CSL Limited in 1994. CSL then sub-licensed the technology to Merck and Co. in 1996, which undertook the large-scale animal and human clinical trials necessary for regulatory approval.

The Phase III clinical trial involved more than twelve thousand women aged sixteen to twenty-six across thirteen countries. It found that women in the vaccinated group had significantly lower occurrence of high-grade cervical lesions related to HPV types 16 and 18 than those in the placebo group. In 2006, following four years of Phase III data, both the Australian Therapeutic Goods Administration and the United States Food and Drug Administration approved the vaccine. Australia became the first country to roll out a national HPV vaccination program in 2007 — initially covering young women, and from 2013 extending to boys.

The vaccine, commercially released as Gardasil, offered complete protection against four HPV strains responsible for approximately seventy percent of cervical cancers. A second vaccine, Cervarix, was independently developed by GlaxoSmithKline using the same VLP approach, following the licensing of Frazer’s intellectual property. The VLP method — the technique born in a Brisbane laboratory from an evening’s work with two proteins — became the foundational technology for both.

The commercialisation pathway was not without friction. A competing US patent application, filed by researchers at Georgetown University approximately one month after Frazer and Zhou’s complete US application, triggered a long and costly patent dispute. In 2007, the US Federal Court ruled in favour of the UQ patent application. A significant factor in that outcome: the lead Georgetown researcher had attended the 1991 Seattle conference, where the Australian team had publicly presented and disclosed its preliminary findings. Priority, in law as in science, had been clearly established.

THE MAN BEHIND THE PARTNERSHIP.

Any honest account of the HPV vaccine must preserve the dual authorship of its core discovery. The history of science frequently reduces collaborative achievement to a single name, and the history of the HPV vaccine has at times done the same disservice. Frazer himself has been consistent in insisting otherwise.

Jian Zhou was born in Hangzhou, Zhejiang, in 1957. He trained in medicine and virology in China before moving to the University of Cambridge in 1988 to continue his research in cancer and virus. It was there he met Frazer. After relocating to UQ in 1990, Zhou was the technical architect of the VLP breakthrough — the researcher who managed to express the HPV capsid proteins in mammalian cells using recombinant DNA technology and who designed the experiments that his wife Xiao-Yi Sun executed to produce the first particles. During his first four years at UQ’s Centre for Immunology and Cancer Research, he published eleven first-author scientific papers in leading virology journals.

Zhou died in March 1999, of hepatitis contracted in China years earlier. He was forty-one years old, and he did not live to see the clinical trials he had helped make possible. In August 2006, when Frazer administered the first official HPV vaccination in the presence of then Queensland Premier Anna Bligh, it was a moment of historic public health significance — but Zhou was not there to share it. Frazer’s public acknowledgement at that moment, documented in contemporary accounts, was unambiguous: the breakthrough could not have been achieved without Zhou’s contribution.

The recognition since has been substantial, if inevitably incomplete. The annual Jian Zhou Memorial Oration, held at UQ since 2000 — the year following his death — brings world-renowned scientists together in his memory. A conference room at UQ bears his name. The Jian Zhou Medal, awarded by the Australian Academy of Health and Medical Sciences and supported by the Frazer Family Foundation, honours scientists making an impact in translational medical science. In 2007, when the US patent lawsuit was finally resolved, Zhou’s heirs were formally confirmed — posthumously — as co-inventors with worldwide priority.

The collaborative character of this discovery is part of its civic meaning. Two researchers from opposite ends of the world — a Scottish-born Australian immunologist and a Chinese virologist — came together in Brisbane and solved a problem that decades of effort elsewhere had not. The University of Queensland was the institution that housed them, funded their laboratory, supported the patent filing, and bore the cost of the subsequent legal dispute.

THE MEASURE OF A VACCINE.

The argument for regarding the HPV vaccine as the University of Queensland’s greatest scientific achievement rests ultimately not on the elegance of the science, nor on the legal primacy established by the patent courts, but on the scale of its human consequences.

Cervical cancer kills approximately a quarter of a million women globally each year, with the burden falling disproportionately on women in low- and middle-income countries where screening infrastructure is limited. It is the fourth most common cancer in women worldwide. The majority of those deaths are preventable. The VLP-based vaccine technology that emerged from UQ’s Centre for Immunology and Cancer Research in 1991 is now the primary mechanism for that prevention.

In Australia, the results of two decades of national vaccination are measurable and stark. The incidence of cervical cancer and mortality from it have halved since the introduction of the HPV vaccine and accompanying screening programs. More precisely: in 2021, for the first time since national cancer records began in 1982, there were no documented cases of cervical cancer in women under twenty-five across the entire country. That is a statistical zero. It represents the first generation of Australian women to grow up effectively immunised against a cancer that once claimed thousands of lives annually.

Australia is now predicted to become the first country in the world to eliminate cervical cancer — defined as fewer than four cases per one hundred thousand women per year — by 2035. Peer-reviewed modelling published in the Medical Journal of Australia in 2026 confirms that Australia remains on track to achieve this, though it notes that equitable outcomes require sustained attention to vaccination and screening access for Aboriginal and Torres Strait Islander women, whose current incidence rates remain nearly double the national average. The elimination of cervical cancer for all Australians, not merely for the well-served, is the unfinished work.

Beyond Australia, the picture is simultaneously encouraging and sobering. More than one hundred countries now include HPV vaccination in their national immunisation programs. The vaccine potentially saves three hundred thousand lives each year at current coverage levels. In the United Kingdom, a study of women vaccinated against HPV at ages twelve or thirteen found that cervical cancer rates were eighty-seven percent lower than in unvaccinated women of comparable age. These numbers represent lives: women who raised their children, who practised their professions, who lived out their decades because a vaccine existed.

The burden on those who have not yet been reached remains acute. More than eighty percent of new cervical cancer cases globally occur in developing countries, where screening infrastructure is scarce and vaccine distribution remains uneven. Frazer himself has consistently framed this as the defining unfinished dimension of the vaccine’s story — working with agencies in Australia and internationally to press for equitable access, arguing that the problem of vaccine availability in low-resource settings is primarily a manufacturing and distribution challenge rather than a question of efficacy.

INSTITUTION AS INFRASTRUCTURE.

The HPV vaccine story is, at one level, a story about two remarkable individuals and a fortunate convergence of expertise. At another level, it is a story about what research universities are for.

It would not have happened without the National Health and Medical Research Council, which funded Frazer’s research on the immune system’s role in cancer from 1986 through to 2022 — a thirty-six year commitment to a research program whose outcomes, in the early years, could not have been predicted. It would not have happened without the Princess Alexandra Hospital, where Frazer conducted concurrent clinical work and where the university’s research and clinical medicine remained in productive proximity. It would not have happened without UniQuest, UQ’s commercialisation arm, which managed the patent prosecution, absorbed the costs of the extended US patent dispute, and channelled the resulting intellectual property into the commercial partnerships that funded trials.

It would not have happened, either, without the institutional culture that allowed Frazer to recruit Zhou, to bring a Chinese virologist to Brisbane on the strength of a shared intellectual interest, and to pursue a research program whose immediate clinical application was far from obvious. The University of Queensland, in this account, is not merely the address where the discovery occurred. It is the enabling condition.

"To achieve a benefit for our University, we also had to prove that we were first to discover the technology, which took much longer than the invention process itself, and ended up in a four-way contest with three American universities."

That remark — Frazer’s own, in an interview with the Australian Academy of Science — catches something important about the relationship between a university and the intellectual property it generates. The patent contest was not merely a commercial matter. It was a question of where a discovery belonged and who would bear the public credit and the public obligation that came with it. The University of Queensland fought that contest, prevailed, and in doing so established the legal and moral foundation for the royalty structures and licensing agreements that have since governed access to the vaccine globally.

The Frazer Institute, named in Frazer’s honour when the UQ Diamantina Institute was renamed at his retirement in 2022, carries this legacy forward. As of 2026, the expanded Institute supports more than three hundred staff across fifty research groups, more than one hundred and eighty higher degree by research students, and generates over sixty million dollars per year in research income. It spans the Herston and Dutton Park campuses and operates within partnerships with the Princess Alexandra Hospital and the Royal Brisbane and Women’s Hospital. The institutional memory of the HPV vaccine’s development is embedded in its structure.

WHAT PERMANENCE LOOKS LIKE.

The HPV vaccine will outlast its inventors, its era, and the particular institutions that produced it. The VLP technology on which it is based has already seeded further applications — vaccines for hepatitis B and HPV variants beyond those covered by the original Gardasil have been developed using the same foundational method. Research programs at UQ continue to investigate VLP-based approaches to vaccines for dengue fever, hepatitis C, and skin cancers caused by related papillomaviruses. The discovery made in a Brisbane laboratory in 1991 set in motion a research tradition that is still deepening.

This continuity of scientific work, in a specific place, over multiple generations of researchers, is one of the things that a research university offers that no other institution quite replicates. The University of Queensland, as an institution with more than a century of civic presence in Queensland, carries this work in a way that is distinct from the pharmaceutical companies that manufactured the vaccine or the governments that subsidised its roll-out. Those actors had roles. But the intellectual origin, the patent, the research tradition, and the ongoing obligation belong to UQ — to St Lucia, to Herston, to Woolloongabba, to the laboratories along the Brisbane River.

The Queensland Foundation’s digital infrastructure project, anchoring institutions to permanent onchain addresses, reflects this same logic of durable civic identity. The namespace uq.queensland is the permanent civic address for the University of Queensland in a distributed identity layer designed to persist beyond the cycles of web infrastructure, domain registrars, and institutional website redesigns. It is, in that sense, the onchain equivalent of the stone buildings at St Lucia: a way of saying that this institution exists, has a history, and will be here tomorrow.

What is worth reflecting on, in closing, is the particular character of the achievement this article has described. The HPV vaccine was not developed by a well-capitalised commercial entity seeking a blockbuster return. It was developed by two researchers working outside normal hours in a publicly funded laboratory, backed by a national medical research council and an institutional commercialisation office, driven by intellectual curiosity about why a virus behaves as it does in the human immune system. The path from that curiosity to the elimination of a cancer is long, tortuous, and improbable — and it began in Queensland.

For a society that is still learning what its research universities are for, and still calibrating what it owes them, the HPV vaccine is an unusually clear answer. It is what can happen when an institution of enduring civic standing is given the resources, the freedom, and the patience to pursue the long work of science without requiring that the destination be visible at the outset. The permanent civic record that uq.queensland anchors to the digital infrastructure of the future is, in part, a record of this — of what Brisbane made possible, and what that making continues to mean for women who will never know the name of the laboratory where it began.